It has been stockpiled by governments all over the world, but does flu medicine Tamiflu even work? A medical journal, BMJ, suggests that it doesn’t.
Roche (PINK:RHHBY), the maker of Tamiflu, claims it has complied with all legal requirements for disclosure concerning the drug. But an editorial in BMJ last month accused Roche of “stonewalling” on the issue.
Roche claims it cannot release any further data because the researchers have not agreed to keep it confidential, the AP reports.
Both the World Health Organization and the U.S. Centers for Disease Control and Prevention recommend Tamiflu, and well as GlaxoSmithKline’s (NYSE:GSK) Relenza, as a treatment for influenza. However, a research team at the Nordic Cochrane Center — which had been hired to evaluate flu drugs — found no evidence that Tamiflu reduced complications for flu sufferers.
Peter Gotzsche — leader of the Nordic Cochrane Center, a research and information center — wrote that European governments should sue Roche for the money spent on Tamiflu. He also said consumers should boycott Roche’s products until the information is forthcoming.
More stories from big pharma:
- Novartis Touts Pipeline of Blockbuster Drugs
- New Pfizer Arthritis Drug Could Be a Blockbuster
- Novartis Flu Vaccine Ban: Who Wins?